| Niche component | Function/role | Mouse studies | Human studies |
|---|---|---|---|
| Vascular endothelium | AML increases blood vessel formation, marrow angiogenesis, nitric oxide production, vascular permeability, and hypoxia | Hussong et al., 2000; Benito et al., 2011; Passaro et al., 2017 | |
| HIF induction associated with B-ALL and AML chemo-resistance | Muz et al., 2014; Wellmann et al., 2004 | ||
| The CXCR4/CXCL12 axis and adhesive interactions through CD44 promote leukemic cell survival | Schneider et al., 2002; Spoo et al., 2007; Passaro et al., 2015; Pitt et al., 2015; Sison and Brown, 2011; Fedorchenko et al., 2013; Godavarthy et al., 2019; Jin et al., 2006; Krause et al., 2006 | ||
| MSCs | |||
| MSCs | Support IKZF1-mutant B-ALL relapse and may promote chemoresistance, but not in T-ALL | Churchman et al., 2015;, Joshi et al., 2014;, Vitanza et al., 2014;, Duan et al., 2014;, Hawkins et al., 2016;, Gomariz et al., 2018; | |
| AML cells induce osteogenic differentiation | Battula et al., 2017 | ||
| Associate with SNS to regulate HSC mobilization and regeneration following chemotherapy | Ho et al., 2019; Katayama et al., 2006; Lucas et al., 2013; Maryanovich et al., 2018; Méndez-Ferrer et al., 2010; Scheiermann et al., 2012 | ||
| CD271+ MSCs | Increase in MDS and AML patients; favor blast expansion through CXCL12 | Geyh et al., 2013, 2016 | |
| Sinusoid-associated Lepr+ stromal cells | Secretion of SCF, critical for HSC function | Ding et al., 2012 | |
| Arteriole-associated NG2+ perivascular cells | Secretion of CXCL12, critical for HSC function | Asada et al., 2017 | |
| Osteolineage cells | |||
| Osteoblasts | AML blocks osteogenesis and decreases osteoblast numbers | Baryawno et al., 2019; Duarte et al., 2018; Krevvata et al., 2014; Hanoun et al., 2014 | Krevvata et al., 2014; El-Ziny et al., 2005; Fitter et al., 2008; Haddy et al., 2001; Sala and Barr, 2007; Shalet, 1996; Sinigaglia et al., 2008 |
| Disease improvement following chemotherapy correlated with increased osteoblast activity | Crofton et al., 1998; El-Ziny et al., 2005; Fitter et al., 2008 | ||
| MDS, MPN, and CML cells remodel endosteal osteoblasts into a self-reinforcing leukemic niche | Medyouf et al., 2014; Schepers et al., 2013 | Medyouf et al., 2014 | |
| PTHR activation differentially affects BCR-ABL1+ CML-like MPN and MLL-AF9+ AML | Krause et al., 2013 | ||
| Restricted by MLL-AF9-AML β2-adrenergic signaling | Hanoun et al., 2014 | ||
| Osx+ cells | Dicer-1 deletion leads to MDS | Raaijmakers et al., 2010 | |
| SDS mutation drives MDS and predicts AML | Zambetti et al., 2016 | Zambetti et al., 2016 | |
| Osteoblast precursors and osteoblasts | Activated β-catenin leads to MDS/AML | Kode et al., 2014; Bhagat et al., 2017; Stoddart et al., 2017 | Kode et al., 2014; Bhagat et al., 2017; |
| Nestin+ cells | SHP2 activating mutations lead to MPN progression | Dong et al., 2016 | |
| Expanded by MLL-AF9+AML–induced sympathetic neuropathy | Hanoun et al., 2014 | ||
| Adipocytes | |||
| Adipocytes | Decreased chemotherapy responsiveness in obese pediatric B-ALL and adult AML patients | Castillo et al., 2016; Castillo et al., 2012; Orgel et al., 2016; Orgel et al., 2014 | |
| Sequester and metabolize commonly used chemotherapeutic drugs | Behan et al., 2009; Pramanik et al., 2013; Sheng et al., 2017 | Sheng et al., 2017 | |
| Secrete glutamine: inhibits the activity of L-asparaginase, a common treatment for ALL | Ehsanipour et al., 2013 | ||
| Fuel AML blasts survival by production of free fatty acids | Shafat et al., 2017; Ye et al., 2016; Li et al., 2018 | Shafat et al., 2017 | |
| Lepr+Esm1+ perivascular cells | Adipocyte progenitor: negatively regulate HSC function | Tikhonova et al., 2019; Naveiras et al., 2009 | |
| Lepr+ cells | Following injury, accumulation of adipocytes in the bone marrow: critical for hematopoietic recovery | Tikhonova et al., 2019; Zhou et al., 2017 | |
| Immune cells | |||
| T cells | CML- and AML-specific T cell responses | Greiner et al., 2006; Molldrem et al., 2000 | |
| Exhaustion contributes to failure of the graft vs. leukemia response in AML patients | Noviello et al., 2019; Toffalori et al., 2019, | ||
| Exhausted subpopulations predict inferior outcome in pediatric B-ALL | Hohtari et al., 2019 | ||
| CSF1R-expressing myeloid cells | Promote AML growth | Edwards et al., 2019 | |
| Macrophages | Promote CLL xenograft survival | Galletti et al., 2016 | |
| Niche component | Function/role | Mouse studies | Human studies |
|---|---|---|---|
| Vascular endothelium | AML increases blood vessel formation, marrow angiogenesis, nitric oxide production, vascular permeability, and hypoxia | ||
| HIF induction associated with B-ALL and AML chemo-resistance | |||
| The CXCR4/CXCL12 axis and adhesive interactions through CD44 promote leukemic cell survival | |||
| MSCs | Support IKZF1-mutant B-ALL relapse and may promote chemoresistance, but not in T-ALL | ||
| AML cells induce osteogenic differentiation | |||
| Associate with SNS to regulate HSC mobilization and regeneration following chemotherapy | |||
| CD271+ MSCs | Increase in MDS and AML patients; favor blast expansion through CXCL12 | ||
| Sinusoid-associated Lepr+ stromal cells | Secretion of SCF, critical for HSC function | ||
| Arteriole-associated NG2+ perivascular cells | Secretion of CXCL12, critical for HSC function | ||
| Osteoblasts | AML blocks osteogenesis and decreases osteoblast numbers | ||
| Disease improvement following chemotherapy correlated with increased osteoblast activity | |||
| MDS, MPN, and CML cells remodel endosteal osteoblasts into a self-reinforcing leukemic niche | |||
| PTHR activation differentially affects | |||
| Restricted by MLL-AF9-AML β2-adrenergic signaling | |||
| Osx+ cells | Dicer-1 deletion leads to MDS | ||
| SDS mutation drives MDS and predicts AML | |||
| Osteoblast precursors and osteoblasts | Activated β-catenin leads to MDS/AML | ||
| Nestin+ cells | SHP2 activating mutations lead to MPN progression | ||
| Expanded by MLL-AF9+AML–induced sympathetic neuropathy | |||
| Adipocytes | Decreased chemotherapy responsiveness in obese pediatric B-ALL and adult AML patients | ||
| Sequester and metabolize commonly used chemotherapeutic drugs | |||
| Secrete glutamine: inhibits the activity of L-asparaginase, a common treatment for ALL | |||
| Fuel AML blasts survival by production of free fatty acids | |||
| Lepr+Esm1+ perivascular cells | Adipocyte progenitor: negatively regulate HSC function | ||
| Lepr+ cells | Following injury, accumulation of adipocytes in the bone marrow: critical for hematopoietic recovery | ||
| T cells | CML- and AML-specific T cell responses | ||
| Exhaustion contributes to failure of the graft vs. leukemia response in AML patients | |||
| Exhausted subpopulations predict inferior outcome in pediatric B-ALL | |||
| Promote AML growth | |||
| Macrophages | Promote CLL xenograft survival | ||
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Please sign in to your personal account to gift article access.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses.
You have reached the limit of 10 links within a 30 day period.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.